Methadone Treatment for Opioid Use Disorder

Improving Access through Regulatory and Legal Change: Proceedings of a Workshop
July 15, 2022

By the National Academies of Sciences, Engineering, and Medicine

Read and Download this Publication (National Academies Press)


Overview

Methadone is a Food and Drug Administration- (FDA-) approved medication for treating opioid use disorder (OUD), a chronic brain disease that affects more than 2.7 million people in the United States aged 12 and older. Despite its effectiveness in saving lives, many barriers impede access to, initiation of, and retention in methadone treatment for OUD. To address these barriers, on March 3 and 4, 2022, the National Academies of Sciences, Engineering, and Medicine hosted a workshop on "Methadone Treatment for Opioid Use Disorder: Examining Federal Regulations and Laws," at the request of the Office of National Drug Control Policy in the Executive Office of the President. This publication summarizes the presentation and discussion of the workshop.

National Academies of Sciences, Engineering, and Medicine 2022. Methadone Treatment for Opioid Use Disorder: Improving Access through Regulatory and Legal Change: Proceedings of a Workshop. Washington, DC: The National Academies Press.

Continue reading...


This publication features commentary by Research Professor Bridget Dooling, who was a member of the Planning Committee on Methadone Treatment for Opioid Use Disorder: Examining Federal Regulations and Law. This publication also cites research by Professor Dooling and Senior Policy Analyst Laura Stanley.